Litcius/Paper detail

Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study

Toni K. Choueiri, Jaime R. Merchan, Robert A. Figlin, David F. McDermott, Edward Arrowsmith, M. Dror Michaelson, Scott S. Tykodi, Elisabeth I. Heath, David R. Spigel, Anishka D'souza, Laurent Kassalow, Rodolfo F. Perini, Donna Vickery, Todd M. Bauer

2025The Lancet Oncology21 citationsDOI

Topics & Concepts

CabozantinibOpen labelMedicineRenal cell carcinomaClear cell renal cell carcinomaUrologyOncologyInternal medicineClinical trialRenal cell carcinoma treatmentCancer, Hypoxia, and MetabolismAdrenal and Paraganglionic Tumors
Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study | Litcius